Back to top
more

Moderna (MRNA)

(Real Time Quote from BATS)

$124.67 USD

124.67
108,127

-0.47 (-0.38%)

Updated Jul 17, 2024 09:52 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Moderna (MRNA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Moderna (MRNA) closed at $137.74, marking a +1.38% move from the previous day.

Pfizer (PFE) Starts Late-Stage Study on Influenza Vaccine

by Zacks Equity Research

Pfizer (PFE) doses the first participants in the phase III study of its investigational mRNA-based influenza vaccine. The study will enroll nearly 25,000 participants.

Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RYH

Pfizer (PFE), BioNTech Omicron BA.4, BA.5 Boosters Get CHMP Nod

by Zacks Equity Research

Pfizer (PFE) and BioNTech (BNTX) get a positive recommendation from CHMP for Omicron BA.4 and BA.5-adapted bivalent vaccines.

Novavax (NVAX) Gets EU Nod for COVID-19 Booster Jab in Adults

by Zacks Equity Research

Novavax (NVAX) gets authorization from the European Union to use its COVID-19 vaccine as a booster dose in adults.

Strength Seen in Galapagos NV (GLPG): Can Its 8% Jump Turn into More Strength?

by Zacks Equity Research

Galapagos NV (GLPG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?

by Zacks Equity Research

Sector ETF report for RYH

Moderna (MRNA) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Moderna (MRNA) closed the most recent trading day at $142.33, moving +0.74% from the previous trading session.

Stock Market News for Sep 9, 2022

by Zacks Equity Research

Wall Street closed higher on Thursday, led by a rally in finance and healthcare stocks.

Novavax's (NVAX) COVID-19 Jab Gets Approval in Switzerland

by Zacks Equity Research

Novavax (NVAX) receives expanded temporary authorization for Nuvaxovid, its COVID-19 vaccine, in Switzerland for adolescents aged 12 to 17 and as a booster in adults aged 18 years and above.

Novavax's (NVAX) COVID-19 Booster Gets CHMP Recommendation

by Zacks Equity Research

The European Medicines Agency's CHMP recommends expanded conditional marketing authorization for Novavax's (NVAX) COVID-19 vaccine as a booster for adults.

Moderna (MRNA) Down 28.4% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Moderna (MRNA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Ekta Bagri headshot

PFE, BNTX and MRNA Omicron Boosters Get Positive CHMP Opinion

by Ekta Bagri

Pfizer (PFE) /BioNTech (BNTX) and Moderna (MRNA) get positive CHMP opinion for Omicron-targeting bivalent booster.

The Zacks Analyst Blog Highlights Pfizer /BioNTec and Moderna's

by Zacks Equity Research

Pfizer /BioNTec and Moderna are part of The Zacks top Analyst Blog.

Kinjel Shah headshot

FDA Authorizes Pfizer, Moderna's Omicron-Based Boosters

by Kinjel Shah

Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) develop the Omicron BA.4/BA.5-adapted bivalent vaccines at the FDA's recommendation.

Kinjel Shah headshot

Pharma Stock Roundup: FDA Authorization of Omicron Boosters, SNY's Xenpozyme & More

by Kinjel Shah

FDA authorizes Pfizer (PFE) & Moderna's (MRNA) Omicron-aimed COVID vaccines & Sanofi's (SNY) new drug, Xenpozyme.

Is the Options Market Predicting a Spike in Moderna (MRNA) Stock?

by Zacks Equity Research

Investors need to pay close attention to Moderna (MRNA) stock based on the movements in the options market lately.

    Biotech Stock Roundup: BMY's Study Update, INCY's Drug Label Expansion, MRNA News

    by Zacks Equity Research

    Regulatory updates from Bristol Myers (BMY) and Incyte (INCY) are a few key highlights from the biotech sector during the past week.

    Moderna's (MRNA) Omicron Based Jab gets Approval in Australia

    by Zacks Equity Research

    Moderna (MRNA) receives provisional approval in Australia for its Omicron-containing bivalent booster vaccine mRNA-1273.214 in adults, making it the first bivalent COVID-19 vaccine approved for use in Australia.

    Company News for Aug 30, 2022

    by Zacks Equity Research

    Companies in The News Are: HTHT,CTLT,MRNA,BA,UPS

    Moderna (MRNA) Sues Pfizer and BioNTech Over COVID Jab

    by Zacks Equity Research

    Moderna (MRNA) sues Pfizer and BioNTech, alleging that Comirnaty infringes on patents that Moderna filed from 2010 to 2016 related to its mRNA technology.

    The Zacks Analyst Blog Highlights Pfizer, BioNTech, Moderna and Morphic

    by Zacks Equity Research

    Pfizer, BioNTech, Moderna and Morphic are included in this Analyst Blog.

    Pfizer (PFE), BioNTech Post Data on COVID Jab for Kids Under 5

    by Zacks Equity Research

    Pfizer (PFE) and BioNTech (BNTX) report updated data, showing that their three-dose COVID-19 vaccine is 73.2% effective in children under five years.

    Moderna (MRNA) Seeks FDA Nod for Omicron-Based COVID Jab

    by Zacks Equity Research

    Moderna's (MRNA) bivalent COVID-19 booster vaccine, mRNA-1273.222, is designed to target the Omicron BA.4 and BA.5 subvariants. The vaccine has been developed specifically for the U.S. market.

    Moderna (MRNA) to Supply Omicron-based COVID Jab in Canada

    by Zacks Equity Research

    Moderna's (MRNA) Omicron-specific bivalent vaccine booster is yet to be approved by Canadian health authorities. The government seeks to purchase 12 million doses of the same in 2022.